Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.77)
# 153
Out of 4,681 analysts
132
Total ratings
56.52%
Success rate
53.93%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Reiterates: Overweight | $65 | $14.41 | +351.08% | 4 | Nov 19, 2024 | |
| SEPN Septerna | Initiates: Overweight | $50 | $24.76 | +101.94% | 1 | Nov 19, 2024 | |
| JANX Janux Therapeutics | Reiterates: Overweight | $100 | $40.18 | +148.88% | 5 | Nov 7, 2024 | |
| ZURA Zura Bio | Reiterates: Overweight | n/a | $2.80 | - | 4 | Oct 18, 2024 | |
| LBPH Longboard Pharmaceuticals | Downgrades: Neutral | n/a | $59.98 | - | 16 | Oct 14, 2024 | |
| SPRY ARS Pharmaceuticals | Reiterates: Overweight | $30 | $13.32 | +125.23% | 4 | Oct 8, 2024 | |
| FDMT 4D Molecular Therapeutics | Downgrades: Neutral | n/a | $7.59 | - | 3 | Sep 23, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $2.51 | - | 2 | Sep 17, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $191 → $205 | $133.51 | +53.55% | 1 | Sep 17, 2024 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Overweight | $90 | $57.39 | +56.82% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $70 | $26.60 | +163.16% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $23.97 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $72.42 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.34 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.64 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.27 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $95.72 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $194.91 | - | 4 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $1.13 | +1,227.43% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $41.30 | +28.33% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $12.75 | +80.39% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $42.12 | +54.32% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $46.21 | +29.84% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $4.13 | +1,110.65% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $35.77 | +109.67% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.52 | +98.41% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $3.23 | +240.56% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $125.89 | +3.26% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $762.34 | -0.31% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $8 | $1.13 | +607.96% | 3 | Sep 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $14.50 | +3.45% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $0.16 | +28,113.17% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $13.17 | +317.62% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.69 | +1,675.15% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $2.75 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $10.00 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $318.55 | -21.52% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $175 → $230 | $0.42 | +55,042.65% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $73.24 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $36.10 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $6.93 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $25.63 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $7.13 | +208.56% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.44 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $65.04 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $181.77 | -47.74% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $65
Current: $14.41
Upside: +351.08%
Septerna
Nov 19, 2024
Initiates: Overweight
Price Target: $50
Current: $24.76
Upside: +101.94%
Janux Therapeutics
Nov 7, 2024
Reiterates: Overweight
Price Target: $100
Current: $40.18
Upside: +148.88%
Zura Bio
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.80
Upside: -
Longboard Pharmaceuticals
Oct 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $59.98
Upside: -
ARS Pharmaceuticals
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $13.32
Upside: +125.23%
4D Molecular Therapeutics
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $7.59
Upside: -
Alector
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.51
Upside: -
Ascendis Pharma
Sep 17, 2024
Maintains: Outperform
Price Target: $191 → $205
Current: $133.51
Upside: +53.55%
Crinetics Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $57.39
Upside: +56.82%
Sep 16, 2024
Reiterates: Overweight
Price Target: $70
Current: $26.60
Upside: +163.16%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.97
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $72.42
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.34
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.64
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.27
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $95.72
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $194.91
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $1.13
Upside: +1,227.43%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $41.30
Upside: +28.33%
Aug 13, 2024
Initiates: Overweight
Price Target: $23
Current: $12.75
Upside: +80.39%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $42.12
Upside: +54.32%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $46.21
Upside: +29.84%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $4.13
Upside: +1,110.65%
May 6, 2024
Reiterates: Overweight
Price Target: $75
Current: $35.77
Upside: +109.67%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.52
Upside: +98.41%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $3.23
Upside: +240.56%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $125.89
Upside: +3.26%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $762.34
Upside: -0.31%
Sep 23, 2022
Upgrades: Outperform
Price Target: $2 → $8
Current: $1.13
Upside: +607.96%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $14.50
Upside: +3.45%
Mar 25, 2021
Initiates: Outperform
Price Target: $45
Current: $0.16
Upside: +28,113.17%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $13.17
Upside: +317.62%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.69
Upside: +1,675.15%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $2.75
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $10.00
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $318.55
Upside: -21.52%
Jun 19, 2018
Upgrades: Outperform
Price Target: $175 → $230
Current: $0.42
Upside: +55,042.65%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $73.24
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $36.10
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $6.93
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $25.63
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $7.13
Upside: +208.56%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $9.44
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $65.04
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $181.77
Upside: -47.74%